注射毒品所致假性股动脉瘤治疗体会(附34例)

目的探讨注射毒品所致假性股动脉瘤的外科疗法。方法对34例注射毒品所致假性股动脉瘤病人的临床资料进行回顾分析。结果13例直接采用ePTFE人造血管行旁路髂外动脉和股浅动脉端侧吻合术,3例采用自体大隐静脉原位移植术,其中1例术后吻合口破裂出血改行ePTFE人造血管行旁路髂外动脉动脉和股浅端侧吻合术,18例股动脉结扎术。全部病例保肢成功。血管移植者术后复查彩色多普勒显示移植血管通畅。结论在患者不能采用合适的自体大隐静脉移植及人造血管移植时,运用结扎股动脉术是治疗注射毒品所致假性股动脉瘤的有效方法。     

17例假性动脉瘤的外科治疗

目的 探讨医源性和毒品注射所致股动脉假性动脉瘤的治疗方法. 方法 17例股动脉假性动脉瘤,4例因瘤体破裂行急诊手术,13例行择期手术.16例先经下腹部切口(腹膜外)暴露髂外动脉控制出血,再经股部切口行瘤体切除,瘤腔清创,分别行ePTFE人造血管髂外动脉和股浅动脉端端吻合术、自身大隐静脉原位移植、局部端端吻合.一例经股部切口直接修补. 结果 17例手术均获成功,无一例发生肢体坏死,其中1例术后发生感染.17例随访5～48个月,平均26个月,保肢成功,无复发. 结论 根据假性动脉瘤局部的实际情况,可采用局部端端吻合、局部修补、自身大隐静脉移植及人造血管移植治疗.     

ע�䶾Ʒ���¼��Թɶ��������������

目的 探讨注射毒品所致假性股动脉瘤外科治疗的疗效。方法 对15例注射毒品所致假性股动脉瘤病人的临床资料进行回顾性分析。结果 15例病人的接受手术治疗，瘤体切除并清创后均采用ePTFE人造血管行髂外动脉和股浅动脉端端吻合术，术后10天及3个月复查彩色多普勒超声显示人造血管血流通畅。结论 戒除毒彻底清创和血管重建是注射毒品所致假性股动脉瘤外科治疗取得成功的关键。     

血管重建治疗注射毒品所致股动脉假性动脉瘤

目的探讨注射毒品所致股动脉假性动脉瘤的外科治疗方法。方法对14例注射毒品所致股动脉假性动脉瘤患者的临床资料进行回顾分析。9例直接采用ePTFE人工血管行原位移植间置术;4例采用自体大隐静脉原位间置移植术;1例行单纯股深动脉结扎术。结果全部病例术后患肢供血良好,无肢体缺血表现,其中11例患者成功随访1～45个月,1例患者出院后出现伤口感染,余患者伤口均在1个月内愈合,现患肢均无缺血症状,活动自如。结论吸毒所致股动脉假性动脉瘤切除后血管重建有利于保证下肢血供,在患者不能提供合适的自体大隐静脉移植时,人工血管原位移植仍是治疗假性股动脉瘤的有效方法。术中彻底清创及术后伤口引流、加强抗炎是预防术后人工血管并发感染的最主要措施。     

注射毒品致股动脉感染性假性动脉瘤的血循环功能重建

目的探讨注射毒品致股动脉感染性假性动脉瘤的血循环重建方法。方法 2003年11月-2009年5月,收治84例因注射毒品致股动脉感染性假性动脉瘤患者。其中男67例,女17例;年龄19～51岁,平均34.6岁。注射毒品时间1～11年,平均2.7年。13例股动脉缺损3～10 cm,其余患者股动脉破口范围1.0 cm×0.3 cm～3.0 cm×0.7 cm。5例行ePTFE人工血管旁路转流,29例行自体大隐静脉移植,24例行股动脉破口修补,26例行股动脉结扎。结果 2例患者术中下肢深静脉血栓脱落致肺栓塞死亡。8例术后出现切口感染,拆除部分或全部缝线,经换药后切口愈合,其余患者切口均Ⅰ期愈合。56例行血管重建或修补的患者,术后足背动脉搏动恢复或增强,无远端肢体骨筋膜室综合征发生;26例行股动脉结扎的患者,术后1周行CT下肢动脉血管重建或下肢动脉造影显示肢体远端均有丰富来自同侧髂内动脉、臀上动脉以及对侧髂内动脉的侧支循环。82例术后获12～36个月随访,平均17.3个月。3例出现间歇性跛行,经扩血管,活血化瘀等药物治疗后好转,肢体功能良好;其余行走正常。结论注射吸毒致股动脉感染性假性动脉瘤应尽早外科手术治疗,彻底清创引流、髂外动脉-股浅动脉旁路带支撑环人工血管或大隐静脉重建以及破口修补,是有效的治疗方法。在感染严重、局部条件无法重建血管的情况下,结扎股动脉也是一种可行选择。     

注射毒品所致假性股动脉瘤的外科治疗(附12例病例分析)

目的探讨注射毒品所致假性股动脉瘤外科治疗的手术方式和疗效。方法对12例注射毒品所致假性股动脉瘤病人的临床资料进行回顾性分析。12例病人均接受手术治疗,瘤体切除并清创后,其中8例行股动脉结扎术,均为急性出血病人,4例采用ePTFE人造血管行髂外动脉和股浅动脉端端吻合术。结果术后10d及3个月复查彩色多普勒超声显示人造血管血流通畅,以及评估患肢有无缺血、坏死。结论：彻底清创、股动脉结扎及必要时的血管重建是对注射毒品所致假性股动脉瘤外科治疗的有效方法。     

血栓闭塞性脉管炎合并动脉硬化闭塞导致下肢缺血的手术治疗

目的 探讨下肢血栓闭塞性脉管炎(thmmboangiitis obliterans,TAO)合并动脉硬化闭塞症(arteriosclerosis obliterans,ASO)手术治疗效果.方法 回顾性分析2007年治疗的TAO合并ASO 6例患者的资料.2例行腹主动脉切开取栓+内膜剥脱+腹主动脉-股深动脉人工血管旁路移植-胭动脉人工血管-小腿动脉自体大隐静脉旁路移植术,1例行腹主动脉切开取栓+内膜剥脱+腹主动脉-右股深动脉人工血管旁路移植-膝下胭动脉人工血管旁路移植术;1例行左髂总动脉-左股深动脉人工血管旁路移植一胫前动脉自体大隐静脉原位移植术,1例行左侧人工血管切开取栓+左股深动脉成形-膝下腘动脉人工血管旁路移植术,1例行右股总动脉-左股总动脉人工血管旁路移植-胫后动脉自体大隐静脉旁路移植术.结果 5例患者术后恢复顺利,1例于术后当天出现股动脉-腘动脉人工血管和远段的大隐静脉桥血栓形成,立即再次手术行人工血管和大隐静脉切开取栓术,并同时行胫后动静脉吻合.6例患者均痊愈出院,无死亡病例.5例患者的下肢远端静息痛完全缓解,1例部分缓解.足部溃疡的2例创面明显缩小,无感染发生.所有患者得到随访,平均随访为6.5个月,3例足部溃疡愈合.1例术后3个月出现左股部切口感染,最终行膝上截肢处理,残端一期愈合.其他5例患者的移植血管通畅,症状缓解.结论 对TAO合并ASO患者如果手术治疗方式恰当,可以取得比较好的疗效.     

注射毒品引致股动脉假性动脉瘤的显微外科治疗

目的 报道长期反复经血管注射毒品引致股动脉上段假性动脉瘤病例的显微外科治疗效果.方法 取股动脉中段(发出股深动脉分支以下一段)代替传统的浅静脉或人造血管作为移植血管修复股动脉上段(发出股深动脉分支以上部位)和髂外动脉下段缺损,股动脉下段与股深动脉端侧吻合重建下肢血液循环共11例.结果 临床治疗11例,术后均成功重建了下肢血液循环,经6～24个月随访观察,平均16个月,未见局部假性动脉瘤复发,足背动脉搏动有力,患肢行走如常.结论 对于无可用自体浅静脉病例,又不能获得人造血管的情况下,用股动脉中段代替传统的浅静脉或人造血管作为移植血管修复股动脉上段和髂外动脉下段缺损,股动脉下段与股深动脉端侧吻合重建下肢血液循环是一种成功的手术方式.     

解剖外腋-股、股-股动脉旁路移植术治疗主髂动脉闭塞症

目的探讨解剖外腋股、股股动脉旁路移植术治疗主髂动脉闭塞症的疗效。方法采用解剖外旁路移植术治疗主髂动脉闭塞症患者３２例。１８例腹主动脉或两侧髂动脉闭塞者采用腋股动脉旁路术，其中２例为腋两股动脉旁路术；１４例单侧髂动脉闭塞者采用股对侧股动脉旁路术。采用腋股动脉旁路的患者，术中８例用真丝人造血管移植，１０例用聚四氟乙烯（ＧｏｒｅＴｅｘ）人造血管；股股动脉旁路术中６例用真丝人造血管移植，１例用自体大隐静脉，７例用ＧｏｒｅＴｅｘ人造血管。结果术后５年随访时，股股动脉旁路术通畅率为７８％，其中真丝人造血管与ＧｏｒｅＴｅｘ人造血管通畅率无明显差异；腋股动脉旁路术中，８例真丝人造血管均已闭塞，１０例ＧｏｒｅＴｅｘ人造血管中１例闭塞，１例发生腹股沟部假性动脉瘤。结论解剖外动脉旁路移植术操作简单，创伤小，无腹部手术并发症，手术安全，术后恢复快。真丝人造血管的使用应限于短段的股股动脉旁路术     

肢体假性动脉瘤的临床诊治(附30例报道)

目的 探讨肢体假性动脉瘤的病因、发病机理以及手术方式的选择,评价各种手术的治疗效果,以提高对假性动脉瘤的诊治水平.方法 30例假性动脉瘤患者(股动脉18例,腘动脉7例,肱动脉2例,桡动脉3例),其中8例为感染或破裂性假性动脉瘤,1例肢体坏死.30例患者均行外科手术治疗,其中11例行假性动脉瘤破口修补术,2例行股动脉结扎术,2例行血管端端吻合术,8例行自体大隐静脉移植术,6例行人工血管移植术,1例行截肢术.结果 30例患者术后恢复顺利,除1例行下肢截肢术外,其余29例术后效果良好.随访7个月～8年,平均(4.4±2.3)年;行人工血管移植术者4例移植段发生血栓,经溶栓治疗后好转,其余血供状况良好.结论 外科手术治疗肢体假性动脉瘤是一种有效的方法.     

Management of femoral artery pseudoaneurysm due to addictive drug injection

Objective: To study surgical management for patients with femoral pseudoaneurysm resulting from addictive drug injection. Methods： Clinical data of 34 patients with femoral pseudoaneurysm resulting from addictive drug injection were retrospectively reviewed. Results: Thirteen patients underwent bypass graft ( end to side) of external iliac artery and superficial femoral artery using expanded polytetrafluoroethylene (ePTFE). Three patients who had an autogenous saphenous vein graftin situs, one of whom was then performed an ePTFE graft when rupture and bleeding occurred at the anastomotic site. Color Doppler image showed patent grafted blood vessels in all the patients after operation. Eighteen patients had their femoral arteries ligated. Limbs of all the 34 patients were saved. Conclusions： Ligating femoral artery is an effective way to treat femoral artery pseudoaneurysm if autogenous saphenous vein graft or artificial vessel graft is not applicable.     

Femoral artery infection complicating intraaortic balloon pumping

Infection of the femoral artery (endarteritis) complicating intraaortic balloon pumping has not been reported. Most reports of complications with this pump have not emphasized wound infection. Whether the balloon is inserted by open or percutaneous technique, infection remains a problem. During the past 7 years, 32 of 50 patients (64 percent) who had intraaortic balloon pump insertion survived balloon removal. In four patients, wound infection of the groin developed with involvement of the femoral artery. Sepsis was due to P. aeruginosa in three patients and E. cloacae in one. All patients required variable degrees of resection of the infected femoral artery wall. One had successful arterial reconstruction with vein patch angioplasty alone after debridement of the vessel wall. In a second patient, resection of the common femoral artery with interposition of a saphenous vein that had been reconstructed to enhance its diameter to that of the femoral artery was accomplished. Dehiscence of a vein patch angioplasty occurred in the remaining two patients with resultant hemorrhage. Further resection of the femoral artery was required with femoro-femoral saphenous vein grafting in one patient and iliofemoral vein grafting in another. Tissue coverage of the reconstructed vessel was best accomplished using a tensor fascis lata myocutaneous flap. All patients survived the infection without amputation.     

内皮化小口径人工血管的研究

目的 探讨成人大隐静脉内皮细胞(HSVECs)种植到人工血管内表面的可行性.方法 酶消化法获取成人大隐静脉内皮细胞,在体外扩增培养13～15 d,将扩增培养的内皮细胞种植于纤维蛋白胶预衬的聚四氟乙烯(ePTFE)人工血管内表面,继续体外培养9～12 d.在不同的时间点,分别剪取部分内皮化的人工血管,行荧光显微镜和扫描电镜检查.结果 内皮细胞种植于人工血管后,扫描电镜下可见细胞在血管表面黏附、生长、增殖.平均孵育12 d后,人工血管腔面见一层均匀的基质,其表面有内皮细胞单层,内皮细胞排列紧密,呈梭形.结论 成人大隐静脉内皮细胞可以种植到人工血管,在体外增殖形成内皮细胞单层,达到内皮化的效果.     

Surgical reconstruction of iliofemoral veins and the inferior vena cava for nonmalignant occlusive disease

PURPOSE: Venous reconstructions are rarely performed, and factors affecting long-term results of bypass grafts implanted in the venous system are not well defined. In this report we updated our experience. METHODS: The clinical data of all patients who underwent venous reconstruction for iliofemoral or inferior vena caval (IVC) occlusion due to nonmalignant disease between January 1985 and June 1999 were retrospectively reviewed. Patients were classified, and outcomes were compared according to the guidelines of the Joint Vascular Societies. RESULTS: Forty-two patients, 23 males and 19 females (mean age, 40 years; range, 16-81), underwent 44 venous reconstructions. Thirty-six patients had limb swelling or venous claudication, 38 had pain, and 14 had healed or active ulcers. The cause of obstruction was congenital in two and acquired in 40 (deep vein thrombosis, 25; trauma, 5; retroperitoneal fibrosis, 4; IVC occlusion devices, 4; others, 2). Eighteen patients underwent saphenous vein crossover grafts (Palma procedure), 17 had expanded polytetrafluoroethylene (ePTFE) grafts implanted (femorocaval, 8; iliocaval, 5; crossfemoral, 3; cavoatrial, 1), 6 patients had spiral vein grafts (5 iliac/femoral and 1 cavoatrial), and 1 underwent femoral vein patch angioplasty. Clinical follow-up averaged 3.5 years (median, 2.5), and graft follow-up with imaging studies averaged 2.6 years (median, 1.6). Seven patients were lost to follow-up. The secondary 3-year patency rate for all reconstructions was 62%. Palma procedures had a 4-year patency rate of 83%. The secondary patency rate of iliocaval and femorocaval ePTFE bypass grafts at 2 years was 54%. The secondary patency was lower in patients with an arteriovenous fistula (P =.023). All ePTFE grafts had a 45% patency rate at 2 years, not significantly different from saphenous vein grafts (83%, P =.16). Clinical scores improved with graft patency (median, 0.0 vs 1.5; P =.044). CONCLUSIONS: Venous reconstructions for iliofemoral or IVC obstruction offer 3-year patency rates of 62%. The Palma procedure with autologous saphenous vein had the best long-term patency, whereas long-term success with ePTFE was moderate. The use of an arteriovenous fistula to improve graft patency remains controversial.     

High early patency of saphenous vein graft for coronary artery bypass harvested with surrounding tissue

BACKGROUND: Surgical trauma to the saphenous vein, used as a conduit for coronary artery bypass grafting, affects their occlusion rate. This study evaluates the early patency of saphenous vein grafts harvested with a pedicle of surrounding tissue that protects the vein from spasm and trauma. METHODS: Fifty-two patients underwent coronary artery bypass grafting with saphenous veins harvested with surrounding tissue. Forty-five patients, who received a total of 124 vein grafts and 42 left internal mammary arteries, underwent angiographic follow-up at a mean of 18 months (9 to 24 months). RESULTS: Patency for saphenous vein grafts was 95.4% and for left internal mammary arteries, it was 93.3%. Twenty-nine of 30 (96.7%) vein grafts anastomosed to arteries 2.0 mm or more, 65 of 67 (97%) grafts to 1.5 mm, and 10 of 13 (77%) anastomosed to 1-mm arteries were patent. Nineteen of 22 (86.4%) vein grafts with flow rates 20 mL/min or less, 32 of 34 (94.1%) with flow between 20 and 40 mL/min, and 50 of 51 (98%) with flow more than 40 mL/min were patent. Other registered surgical and clinical factors did not contribute to vessel occlusion. CONCLUSIONS: Early patency rate of saphenous veins harvested with surrounding tissue is very high, even in saphenous vein grafts demonstrating low blood flow. Preservation of graft endothelium using our harvesting technique may be the explanation of this success.     

Infrainguinal ePTFE vascular graft with bioactive surface heparin bonding. First clinical results

AIM: The ultimate aim of improved expanded polytetrafluoroethylene (ePTFE) vascular graft design is to achieve patency rates in femoropopliteal bypass grafting comparable with autologous saphenous vein grafts. Enhanced thromboresistance of the ePTFE material by bioactive surface heparin bonding is one conceivable path toward this goal. This retrospective study was performed to collect the first clinical data for a new ePTFE graft with bioactive surface heparin immobilization. METHODS: Between March 2003 and February 2004, 43 femoropopliteal or femorocrural ePTFE vascular prostheses with bioactive end-point immobilized heparin (Gore-Tex Propaten Vascular Graft), using the Car-meda BioActive Surface technology, were implanted in 40 patients. Twelve prostheses were implanted in above-knee and 31 in below-knee position. The indication for bypass grafting was limb-threatening ischemia in 88% of the patients. The mean follow-up was 16.6 months. RESULTS: The primary 1-year patency was 91% for above-knee bypass grafts and 92% for below-knee bypass grafts. The 2-year primary patency rate for above-knee bypass grafts was 68% and 81% for below-knee bypass grafts. Limb salvage was achieved in 98%. The perioperative mortality was 0%, but during follow-up 22% of the patients died with patent bypass grafts. CONCLUSIONS: While conventional ePTFE grafts, particularly in the below-knee position, have shown poor results even in the short-term, the bioactive heparinized ePTFE graft evaluated in this study provides patency rates comparable with autologous vein grafts. Because the influence of luminal heparin bonding is not only limited to thromboresistance but has impact on, amongst other elements, protein adsorption (thereby improving hemocompatibility), a continuous effect for long-term patency could also be expected.     

一期大隐静脉动脉化治疗下肢严重缺血症

为探索一期大隐静脉动脉化治疗下肢严重缺血症的效果，采用自体头静脉或Ｇｏｒｅｔｅｘ人造血管，在大隐静脉与患肢股动脉或髂外动脉之间搭桥，治疗８９例１２７侧下肢严重缺血症患者。结果表明，术后下肢缺血性疼痛消失，皮肤温度及颜色恢复正常，足趾及跖部创面愈合，多普勒超声探测及动脉造影提示患足血供良好。认为，一期大隐静脉动脉化搭桥术不影响静脉血回流，方法简便，效果良好；使用血管搭桥可使这一术式应用范围更广     

Long-term Outcome of Femoral Above-knee Popliteal Artery Bypass Using Autologous Saphenous Vein Versus Expanded Polytetrafluoroethylene Grafts

Despite a recent flurry of publications on preferred techniques for femoral above-knee popliteal artery bypass, controversy persists over the use of autologous saphenous vein and expanded polytetrafluoroethylene (ePTFE) grafts. The purpose of this study was to compare our long-term results using these two bypass materials. In a series of 474 infrainguinal bypasses performed between January 1993 and December 1998, we performed a total of 75 femoral above-knee popliteal artery bypass using an autologous saphenous vein graft in 48 cases (64%) and an ePTFE graft in 27 cases (36%). Prosthetic grafts were used by choice in 17 cases and by necessity due to the absence of useable vein in 10 cases. There were 55 men and 18 women with a mean age of 70 years. The indication for bypass was lower extremity arterial occlusive disease at stage II in 17 cases (22.7%), stage III in 9 cases (12%), and stage IV in 36 cases (48%); subacute ischemia in 8 cases (10.7%); and femoropopliteal aneurysm in 5 cases (6.7%). Preoperative arteriography demonstrated three patent leg arteries in 15.5% of cases, two patent leg arteries in 43.5%, and one patent leg artery in 41%. There was no significance difference between the vein graft and ePTFE graft groups with regard to indications and arteriographic findings. No patient died during the immediate postoperative period. The mean duration of follow-up was 25.5 months (range, 3 to 108 months). The primary patency rate at 4 years was 82.2 ± 8% for venous bypass vs. 80.6 ± 11.8% for ePTFE bypass (p = 0.42). The secondary patency rate at 4 years was 84.7 ± 7.4% for vein bypasses and 79.5 ± 12% for ePTFE bypasses (p = 0.26). In our experience, there was no statistically significant difference in long-term outcome of femoral above-knee popliteal artery bypass using autologous vein grafts or prosthetic ePTFE grafts. Presented at the Seventeenth Annual Meeting of the Société de Chirurgie Vasculaire de Langue Française, May 29-31, 2002, Liege, Belgium.